Cargando…

Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery

Colorectal cancer is one of the most commonly diagnosed cancers worldwide. The treatment consists of surgical resection, systemic chemotherapy, and new biological agents. One more recently emerging treatment option is oncolytic virotherapy. Although the use of the new treatment methods shows improve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tilgase, Andra, Olmane, Evija, Nazarovs, Jurijs, Brokāne, Linda, Erdmanis, Romualds, Rasa, Agnija, Alberts, Pēteris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2018
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167672/ https://www.ncbi.nlm.nih.gov/pubmed/30283278 http://dx.doi.org/10.1159/000492210

Ejemplares similares

A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir(®)
por: Ismailov, Zaurbek, et al.
Publicado: (2019)

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient
por: Brokāne, Linda, et al.
Publicado: (2019)

Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report
por: Proboka, Guna, et al.
Publicado: (2019)

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir
por: Proboka, Guna, et al.
Publicado: (2020)

Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines
por: Tilgase, Andra, et al.
Publicado: (2020)

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report
por: Proboka, Guna, et al.
Publicado: (2018)

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report
por: Sorokins, Vladimirs, et al.
Publicado: (2020)

ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report
por: Jaunalksne, Inta, et al.
Publicado: (2020)

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir(®) therapy: A case report
por: Pumpure, Elizabete, et al.
Publicado: (2020)

Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro
por: Tilgase, Andra, et al.
Publicado: (2018)

4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir administered intramuscularly with a 4-week recovery period
por: Piwoni, Katarzyna, et al.
Publicado: (2021)

Comment on Hietanen et al. Cytolytic Properties and Genome Analysis of Rigvir(®) Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. Viruses 2022, 14, 525
por: Alberts, Pēteris
Publicado: (2022)

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study
por: Doniņa, Simona, et al.
Publicado: (2015)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
por: Babiker, Hani M, et al.
Publicado: (2017)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
por: Babiker, HM, et al.
Publicado: (2019)

Genome Sequences of RIGVIR Oncolytic Virotherapy Virus and Five Other Echovirus 7 Isolates
por: Hietanen, Eero, et al.
Publicado: (2018)

Cytolytic Properties and Genome Analysis of Rigvir(®) Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates
por: Hietanen, Eero, et al.
Publicado: (2022)

Erratum: Melanoma Unknown Primary Brain Metastasis Treatment With ECHO-7 Oncolytic Virus Rigvir: A Case Report
Publicado: (2018)

Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report: Erratum
Publicado: (2019)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Whole Genome Sequencing Analysis of a Stage IV Colon Cancer Patient with a 10-Year Disease-Free Survival following Systemic Chemotherapy/Bevacizumab
por: Yeatman, Timothy J., et al.
Publicado: (2018)

Long-Term Colon Stent Patency for Obstructing Colorectal Cancer Combined with Bevacizumab
por: Latenstein, Anouk E.J., et al.
Publicado: (2017)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
por: Powell, Erin D., et al.
Publicado: (2009)

A Patient with Transverse Colon Cancer Complicated by Cowden Syndrome Administered FOLFOXIRI + Bevacizumab Therapy
por: Takehara, Kazuhiro, et al.
Publicado: (2023)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension
por: Bertoli, Luigi F., et al.
Publicado: (2017)

Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
por: Līcīte, Baiba, et al.
Publicado: (2021)

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
por: Wang, Feng, et al.
Publicado: (2022)

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

Reply to Alberts, P. Comment on “Hietanen et al. Cytolytic Properties and Genome Analysis of Rigvir(®) Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. Viruses 2022, 14, 525”
por: Hietanen, Eero, et al.
Publicado: (2022)

Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
por: Otsu, Satoshi, et al.
Publicado: (2014)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers
por: Niciporuka, Rita, et al.
Publicado: (2021)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vs1fkfdp6t8kbo5ii0hihnrrl2